Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 10;10(3):952-955.
doi: 10.1016/j.ekir.2024.12.009. eCollection 2025 Mar.

Recurrence of Phospholipase A2 Receptor-Associated Membranous Nephropathy in the Absence of Serum Anti-Phospholipase A2 Receptor Antibodies Reappearance

Ilias Bensouna  1 , Marion Delafosse  1 , Claire Cartery  2 , Thomas Stehlé  3   4 , Clementine Rabate  5 , Fanny Boullenger  6 , David Buob  7   8 , Jean-Jacques Boffa  1   8 , Karine Dahan  1 , Emmanuel Esteve  1   8
Affiliations

Recurrence of Phospholipase A2 Receptor-Associated Membranous Nephropathy in the Absence of Serum Anti-Phospholipase A2 Receptor Antibodies Reappearance

Ilias Bensouna et al. Kidney Int Rep. .
No abstract available

Keywords: anti-PLA2R antibody; idiopathic membranous nephropathy; relapse; seronegative.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biological and immunological presentation of patients with MN with seronegative relapse. Evolution of (a) UPCR and (b) serum albumin level at baseline, clinical relapse, and treatment, 6 months and 12 months after treatment for each patient. Independent patient trajectories are represented by grey lines. Median is represented by the single blue line, whereas interquartiles are represented by dotted blue lines. (c) Proteinuria (UPCR, g/g), serum albumin (g/l), and anti-PLA2R antibody levels measured by IIF assay and ELISA (gray lines) are shown at the initial flare and during follow-up, up to 24 months postflare (M24). Additional time points include 12, 6, and 3 months before clinical relapse (R-12, R-6, R-3), at the time of clinical relapse (R), and up to 22 months after relapse (R-22). UPCR < 0.3 g/g and albumin > 35 g/l are indicated in green; UPCR between 0.3 and 3 g/g and albumin between 30 and 35 g/l have been indicated in yellow; and UPCR > 3 g/g and albumin < 30 g/l have been indicated in red. Seronegativity by IIF is shown in green, whereas seropositivity is shown in red. Anti-PLA2R titers measured by ELISA below the laboratory threshold of 14 RU/ml but above 2 RU/ml are represented in yellow. For patients receiving immunosuppressive therapy at clinical relapse, the month of treatment initiation is highlighted with a red frame. ELISA, enzyme-linked immunosorbent assay; IIF, immunofluorescence; PLA2R, phospholipase A2 receptor; UPCR, urinary protein-to-creatinine ratio.
See this image and copyright information in PMC

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–S276. doi: 10.1016/j.kint.2021.05.021. - DOI - PubMed
    1. Francis J.M., Beck L.H., Salant D.J. Membranous nephropathy: A journey from bench to bedside. Am J Kidney Dis Off J Natl Kidney Found. 2016;68:138–147. doi: 10.1053/j.ajkd.2016.01.030. - DOI - PMC - PubMed
    1. Qin H.Z., Zhang M.C., Le W.B., et al. Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. J Am Soc Nephrol. 2016;27:3195–3203. doi: 10.1681/ASN.2015080953. - DOI - PMC - PubMed
    1. Leung W.Y., Wu H.H.L., Nair B., Woywodt A., Ponnusamy A. Unexpected seronegative response in relapsed PLA2R-associated membranous nephropathy. Clin Kidney J. 2024;17 doi: 10.1093/ckj/sfae189. - DOI - PMC - PubMed
    1. Pourcine F., Dahan K., Mihout F., et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS One. 2017;12 doi: 10.1371/journal.pone.0173201. - DOI - PMC - PubMed

LinkOut - more resources